EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

Ahmed Hasbi, Bertha K Madras, Susan R George

Brain Sciences · 14.02.2023 · 13 (2) · 325

DOI: 10.3390/brainsci13020325 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 14.02.2023. Verfasst von Ahmed Hasbi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, CIHR, NIDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and depression are cited as either a primary or a secondary reason for the use of cannabinoids.

Aim

The purpose of this review is to explore the association between depression or anxiety and the dysregulation of the endogenous endocannabinoid system (ECS), as well as the use of phytocannabinoids and synthetic cannabinoids in the remediation of depression/anxiety symptoms. After a brief description of the constituents of cannabis, cannabinoid receptors and the endocannabinoid system, the most important evidence is presented for the involvement of cannabinoids in depression and anxiety both in human and from animal models of depression and anxiety. Finally, evidence is presented for the clinical use of cannabinoids to treat depression and anxiety.

Conclusions

Although the common belief that cannabinoids, including cannabis, its main studied components—tetrahydrocannabinol (THC) and cannabidiol (CBD)—or other synthetic derivatives have been suggested to have a therapeutic role for certain mental health conditions, all recent systematic reviews that we report have concluded that the evidence that cannabinoids improve depressive and anxiety disorders is weak, of very-low-quality, and offers no guidance on the use of cannabinoids for mental health conditions within a regulatory framework. There is an urgent need for high-quality studies examining the effects of cannabinoids on mental disorders in general and depression/anxiety in particular, as well as the consequences of long-term use of these preparations due to possible risks such as addiction and even reversal of improvement.

Schlagwörter

Stichwörter der Autor:innen

CB1RCBDTHCanxietycannabinoidcannabinoid receptorscannabisdepressionendocannabinoid system

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • McLean Hospital, Belmont, MA 02478, USA.
  • Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.

Förderung

  • NIDA NIH HHS
  • CIHR
  • NIDA

Zitieren

APA

Hasbi, A., Madras, B. K., & George, S. R. (2023). Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sciences, 13(2), 325. https://doi.org/10.3390/brainsci13020325

Vancouver

Hasbi A, Madras BK, George SR. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sciences. 2023;13(2):325. doi:10.3390/brainsci13020325

BibTeX
@article{Hasbi2023,
  author = {Hasbi, Ahmed and Madras, Bertha K and George, Susan R},
  title = {Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review},
  journal = {Brain Sciences},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {325},
  doi = {10.3390/brainsci13020325}
}
Kostenlos starten →